<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 26, 2000
VIROPHARMA INCORPORATED
-----------------------
(Exact name of issuer as specified in charter)
DELAWARE 0-021699 23-2789550
(State or Other (Commission (I.R.S. Employer
Jurisdiction file Identification
of Incorporation or number) Number)
Organization)
405 EAGLEVIEW BOULEVARD
EXTON, PENNSYLVANIA 19341
(Address of principal executive offices)
(610) 458-7300
(Registrant's telephone number, including area code)
<PAGE>
Item 5 - Other Events.
As is more fully described in the attached press release that is
incorporated herein by reference, on October 26, 2000, ViroPharma Incorporated
reported financial results for the third quarter ended September 30, 2000.
This report, including the press release attached hereto, contains forward-
looking statements that involve a number of risks and uncertainties, including
those relating to ViroPharma's expectation that patient studies with VP50406 for
the treatment of hepatitis C will start by the end of 2000. There can be no
assurance that such studies can be initiated on a timely basis, or at all, or
that any such trials can be successfully concluded. Investigational
pharmaceutical products, such as ViroPharma's product candidates for hepatitis
C, require significant time and effort for research and development, laboratory
testing and clinical testing prior to regulatory approval and commercialization.
As a result, the initiation and performance of such studies as described in this
report, including the press release attached hereto, are subject to risks and
uncertainties. Neither the FDA nor any other regulatory authority has approved
any of ViroPharma's product candidates for commercialization. There can be no
assurance that FDA or other regulatory authority approval for any product
candidate under development by ViroPharma will be granted on a timely basis or
at all. Even if approved, there can be no assurance that such drug candidates
will achieve market acceptance. These factors, and other factors that could
cause future results to differ materially from the expectations expressed in
this report, including the press release attached hereto,, include, but are not
limited to, those described in ViroPharma's most recent Registration Statement
on Form S-3 filed with the Securities and Exchange Commission. The forward-
looking statements contained in this report, including the press release
attached hereto, may become outdated over time. ViroPharma does not assume any
responsibility for updating any forward-looking statements.
Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Incorporated Press Release dated October 26,
2000
<PAGE>
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ViroPharma Incorporated
Date: October 26, 2000 By: /s/ Michel de Rosen
-------------------
Michel de Rosen
President and Chief Executive Officer
<PAGE>
Index to Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Incorporated Press Release dated October 26, 2000
